Skip to content

A study on the analgesic effect and action of single epidural administration of morphine and hydromorphone in postpartum women after vaginal delivery

Stepwise multimodal drug analgesia for postpartum women after vaginal delivery based on single epidural administration

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108999
Enrollment
Unknown
Registered
2025-09-10
Start date
2025-09-10
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum pain

Interventions

Hydromorphone Group (H):Before removing the epidural catheter at the end of labor analgesia, 10 ml of sterile normal saline containing 0.5 mg of hydromorphone is injected into the epidural space.
Morphine group (M):Before removing the epidural catheter at the end of labor analgesia, 10 ml of sterile normal saline containing 1 mg of morphine is injected into the epidural space.
Blank:The epidural catheter should be removed immediately following the conclusion of labor analgesia.

Sponsors

Maternal and Child Health Hospital of Hubei Province
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 20-40 years who underwent epidural labor analgesia and voluntarily signed the consent form to participate in this trial; 2. American Society of Anesthesiologists (ASA) grade I.~II; 3.18.5<=BMI<=30; 4. No analgesic drug use within 3 months; 5. No mental disorders, intellectual disabilities and other diseases; 6. No history of drug abuse, drug abuse, or alcoholism; 7. Be able to communicate well and complete relevant questionnaires and questions.

Exclusion criteria

Exclusion criteria: 1. Patients and their families refuse to sign the informed consent form to participate in the trial; 2. ASA level III or above; 3. Previous history of allergy to narcotic drugs, allergy to the active ingredients and excipients of the drugs used; 4. Severe congenital heart disease or abnormal liver and kidney function (ALT<2ULN; SCr <1.5 times baseline, eGFR <25%); 5. Suffering from conscious disorders; 6. History of neurological diseases and mental illness; 7. There is a serious risk of increased blood pressure or intracranial pressure.

Design outcomes

Primary

MeasureTime frame
Visual pain score;blood pressure;hreat rate;oxygen saturation;Edinburgh Postnatal Depression Scale (EPDS);Additional analgesic treatment;The perineal condition of the parturient;

Secondary

MeasureTime frame
degree of satisfaction;adverse event;Urination and defecation;Apagar score;

Countries

China

Contacts

Public ContactQuan Yingyao

Maternal and Child Health Hospital of Hubei Province

quanyingyao266@126.com+86 186 6507 3455

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026